Trial reportNeuroImage. Clinical2016
Longitudinal imaging in
Open access · goldAbstract readClinical Trial
In one paragraph
Trial report in NeuroImage. Clinical, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 5 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 5 pooled it
5.6field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
54 citing papers in PubMed, 5 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Pre-symptomatic radiological changes in frontotemporal dementia: propagation characteristics, predictive value and implications for clinical trials.Brain imaging and behavior · 2022Pooled it
- Structural magnetic resonance imaging findings and histopathological correlations in motor neuron diseases-A systematic review and meta-analysis.Frontiers in neurology · 2022Pooled it
- The presymptomatic phase of amyotrophic lateral sclerosis: are we merely scratching the surface?Journal of neurology · 2021Pooled it
- The imaging signature of C9orf72 hexanucleotide repeat expansions: implications for clinical trials and therapy development.Brain imaging and behavior · 2021Pooled it
- Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020Pooled it
- Longitudinal functional network connectivity changes across the clinical stages of C9orf72 hexanucleotide repeat expansion carriers.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Composite grey matter fingerprints for genetic frontotemporal dementia.Journal of neurology, neurosurgery, and psychiatry · 2026Article
- Brain metabolic connectivity in ALS due to C9ORF72 hexanucleotide expansion: a [European journal of nuclear medicine and molecular imaging · 2026Article
- Divergent Brain Network Activity in Asymptomatic C9orf72 and SOD1 Variant Carriers Compared With Established Amyotrophic Lateral Sclerosis.Human brain mapping · 2025Article
- Multiparametric MRI-based biomarkers in the non-fluent and semantic variants of primary progressive aphasia.Journal of neurology · 2025Article
- Molecular pathology, developmental changes and synaptic dysfunction in (pre-) symptomatic human C9ORF72-ALS/FTD cerebral organoids.Acta neuropathologica communications · 2024Article
- Mismatch between clinically defined classification of ALS stage and the burden of cerebral pathology.Journal of neurology · 2024Article
- Resting-state fMRI functional connectome of C9orf72 mutation status.Annals of clinical and translational neurology · 2024Article
- The pursuit for markers of disease progression in behavioral variant frontotemporal dementia: a scoping review to optimize outcome measures for clinical trials.Frontiers in aging neuroscience · 2024Article
- Roadmap for C9ORF72 in Frontotemporal Dementia and Amyotrophic Lateral Sclerosis: Report on the C9ORF72 FTD/ALS Summit.Neurology and therapy · 2023Article
- Presymptomatic grey matter alterations in ALS kindreds: a computational neuroimaging study of asymptomatic C9orf72 and SOD1 mutation carriers.Journal of neurology · 2023Article
- Hippocampal Metabolic Alterations in Amyotrophic Lateral Sclerosis: A Magnetic Resonance Spectroscopy Study.Life (Basel, Switzerland) · 2023Article
- Thalamic pathology in frontotemporal dementia: Predilection for specific nuclei, phenotype-specific signatures, clinical correlates, and practical relevance.Brain and behavior · 2023Review
- Hypothalamic subregion abnormalities are related to body mass index in patients with sporadic amyotrophic lateral sclerosis.Journal of neurology · 2022Article
- Distinct patterns of progressive gray and white matter degeneration in amyotrophic lateral sclerosis.Human brain mapping · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Mary Kay FloeterMotor Neuron Disorders Unit, OCD, NINDS, NIH 10 Center Drive Room 7-5680 Bethesda, MD 20892-1404, United States.
Devin BageacMotor Neuron Disorders Unit, OCD, NINDS, NIH 10 Center Drive Room 7-5680 Bethesda, MD 20892-1404, United States.
Laura E DanielianMotor Neuron Disorders Unit, OCD, NINDS, NIH 10 Center Drive Room 7-5680 Bethesda, MD 20892-1404, United States.
Laura E BraunMotor Neuron Disorders Unit, OCD, NINDS, NIH 10 Center Drive Room 7-5680 Bethesda, MD 20892-1404, United States.
Bryan J TraynorNeuromuscular Disease Research Section LNG, NIA, NIH 35 Convent Drive Room 1A213 Bethesda, MD 20892-3707, United States.
Justin Y KwanDepartment of Neurology, University of Maryland, 110 S. Paca Street, Baltimore, MD 21201, United States.
National Institute of Neurological Disorders and Stroke · USNational Institutes of Health · USUniversity of Maryland, Baltimore · US
Funding
Natural history and biomarker discovery in C9orf72 Amyotrophic lateral sclerosis and frontotemporal dementiaZIANS003146 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI FLOETER, MARY KAY · 2015 to 2020
$6.6MGenome wide SNP analysis in Amyotrophic Lateral SclerosisZ01AG000933 · NIA · NATIONAL INSTITUTE ON AGING · PI SINGLETON, ANDREW · 2008 to 2008
$192kIntramural NIH HHS Z01 AG000933
Abstract
Expansion mutations in the
Indexed as
Disease ProgressionAdultAgedAmyotrophic Lateral SclerosisAtrophyC9orf72 ProteinCerebral CortexCerebral VentriclesFemaleFollow-Up StudiesFrontotemporal DementiaHeterozygoteHumansMagnetic Resonance ImagingMaleMiddle AgedC9orf72 ProteinC9orf72 protein, humanALS, amyotrophic lateral sclerosisALSFRS-R, ALS functional rating scale — revisedAmyotrophic lateral sclerosisANCOVA, analysis of covarianceANOVA, analysis of variancebvFTD, behavioral variant frontotemporal dementiaC9orf72C9 +, subjects with C9orf72 expansion mutationsCortical thicknessCSF, cerebrospinal fluidDiffusion tensor imagingDRS-2, Mattis dementia rating scaleDTI, diffusion tensor imagingFBI, frontobehavioral inventoryFDR, false discovery rate correctionFrontotemporal dementiaFTD, frontotemporal dementiaMRI, magnetic resonance imagingsALS, sporadic ALSSD, standard deviationTIV, total intracranial volumeVentricular volume
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.